摘要
目的探讨孟鲁司特钠联合阿奇霉素治疗小儿支原体肺炎（MP）的临床应用效果。方法将82例MP患儿随机分为观察组和对照组各41例，对照组在常规治疗的基础上口服阿奇霉素，观察组在对照组的基础上加用孟鲁司特钠咀嚼片口服。比较两组患儿的体温恢复时间、咳嗽消失时间、喘息消失时间以及随访6个月内发生哮喘的情况。结果观察组与对照组的体温恢复时间、咳嗽消失时间、喘息消失时间分别为（3．8±1．1）d、（21．4±3．4）d、（8．1±1．7）d和（3．5±1．5）d、（8．1±2．S）d、（6．0±1．5）d；观察组与对照组患儿支原体肺炎感染后继发哮喘的发病率分别为9．76％和39．02％；观察组与孟鲁司特钠相关的可疑不良反应1例，表现为皮疹，未经停药后自行缓解，未见其他明显不良反应。结论孟鲁司特钠联合阿奇霉素治疗小儿MP具有较好的临床效果，不但能明显改善患儿的临床症状、体征，且复发率低、并发症少，值得临床推广应用。
Objective To investigate the clinical effect of montelukast sodium combined with the azithromycin treatment of mycoplasma pneumonia（MP）. Methods 82 cases of MP children were randomly divid-ed into observation group and control group, 41 cases in each group, the control group was treated by the azithromycin on the basis of the conventional treatment, the observation group was treated by montelukast sodium on the basis of the treatment for control group, and then compared the children＇ s body temperature recovery time, cough disappeared time, wheezing disappeared time, and the asthma follow-up occurred within 6 months between the two groups, Results The body temperature recovery time of the observation group and the control group were （3.8 ± 1.1 ） d and （3.5 ± 1.5 ） d respectively, the differences were not statistically significant between the two groups （P〉0.05）. The coughing and wheezing disappeared time in the observation group and the control group were（21.4 ± 3.4） d, （8.1± 2.5） d and（8.1 ±1.7） d,（6.0± 1.5） d,the differences were statistically significant be- tween the two groups （P〈0.05）. Disease incidence of the myeoplasma pneumoniae infection secondary to asthma in the observation group and the control group were 39.02% and 9.76%, the differences were statistically signifi- cant between the two groups（ P〈0.01 ）. One case of suspected adverse reactions associated with montelukast sodi- um in the observation group, the incidence of 2.44%, expressed as rash, without spontaneous remission after dis- continuation. There were no other significant adverse reactions occurred. Conchmion Montelukast sodium azithromycin treatment for children with MP has better clinical effects, not only can significantly improve the clin- ical symptoms and signs of the children, but also can reduce the recurrence rate, with fewer complications, which is worthy of clinical application.
出处
《国际医药卫生导报》
2013年第2期183-186,共4页
International Medicine and Health Guidance News
关键词
支原体肺炎
小儿
孟鲁司特钠
阿奇霉素
Mycoplasma pneumonia
Pediatric
Montelukast sodium
Azithromycin
